Paradigm share price tanks despite positive clinical trial update

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a speccy biotech that could sink or soar.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is down 7% to $1.95 today, despite the biotech researcher today telling the market that its first 'investigational new drug' (IND) application had been approved by the US healthcare regulator the FDA.

This does not mean the FDA has approved a Paradigm drug for potential commercialisation, but rather means the FDA has approved the drug's safety data and potential use to meet "an unmet clinical need". In other words Paradigm now has the green light or 'seal of approval' to conduct further trials, but there's no guarantee these will be successful.

As the real challenge of designing successful Phase III clinical trials to meet the FDA's approval for the commercialisation of a new drug is still ahead of it.

Paradigm flagged that it intends to meet the FDA in the future to launch other NDAs for the treatment of osteoarthritis and "the rare disease mucopolysaccharidosis". It also plans to meet with the Australian healthcare regulator the TGA to seek provisional approval for undefined products.

At a $1.95 share price it has a market value around $375 million based on 192.2 million shares on issue. As such we can see shareholders are confident this could turn out to be a rare biotech success story. 

Other more speculative biotech businesses heavily backed include Mesoblast limited (ASX: MSB) and Next Science Ltd (ASX: NXS).

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 5 December 2024

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Multiracial happy young people stacking hands outside - University students hugging in college campus - Youth community concept with guys and girls standing together supporting each other.
Share Market News

Here's how the ASX 200 market sectors stacked up last week

The worst-performing market sector of 2024 was the best performer in the first week of 2025.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Broker Notes

These ASX 200 shares could rise 20% and 50% in 2025

Analysts are tipping these shares to beat the market this year. Let's see why.

Read more »

Girls at a party are surrounded by gold streamers, a golden ball and are having a fun time.
Best Shares

New Year's resolution! Top ASX shares for beginner investors in 2025

Planning to bolster your financial future this year?

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Gainers

Why Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higher

These shares are ending the week with a bang. But why? Let's find out.

Read more »

A man looks down with fright as he falls towards the ground.
Share Fallers

Why Appen, Brainchip, Liontown, and Mesoblast shares are falling today

These shares are ending the week in the red. But why?

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares.

Read more »

A woman blows what looks like colourful dust at the camera, indicating a positive or magic situation.
Share Market News

Why did the NAB share price jump 21% in 2024?

It was a good year for this big four bank. Let's see what happened over the 12 months.

Read more »